# Combination Therapy Using Lenalidomide (Revlimid)- Low Dose Dexamethasone and Rituximab for Treatment of Rituximab-Resistant, Non-Aggressive B-Cell Lymphomas

> **NCT00783367** · PHASE2 · COMPLETED · sponsor: **Abramson Cancer Center at Penn Medicine** · enrollment: 50 (actual)

## Conditions studied

- Follicular Lymphoma
- Marginal Zone B-Cell Lymphoma
- MALT Lymphoma
- Lymphoma of Mucosa-Associated Lymphoid Tissue
- Lymphoma, Small Lymphocytic
- Waldenstrom Macroglobulinemia
- Mantle-Cell Lymphoma

## Interventions

- **DRUG:** Lenalidomide
- **DRUG:** Dexamethasone
- **DRUG:** Rituximab

## Key facts

- **NCT ID:** NCT00783367
- **Lead sponsor:** Abramson Cancer Center at Penn Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-07
- **Primary completion:** 2012-11-14
- **Final completion:** 2020-11-23
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2023-03-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00783367

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00783367, "Combination Therapy Using Lenalidomide (Revlimid)- Low Dose Dexamethasone and Rituximab for Treatment of Rituximab-Resistant, Non-Aggressive B-Cell Lymphomas". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT00783367. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*